

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

X



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)  
[Back](#)

[About MSK](#)  
[Cancer Treatment](#)  
[Biosimilars](#)  
[Learn About Cancer & Treatment](#)

## ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

## FOR THE MEDIA



## Email

[iasonosa@mskcc.org](mailto:iasonosa@mskcc.org)

## Education

University of Albany

## Current Research Interests

With over 25 years of experience in both the pharmaceutical industry and academic medical centers, Dr. Iasonos has dedicated her career to advancing oncology research and improving clinical trial outcomes. Her expertise spans from early drug development, safety and efficacy data analysis to clinical trial design, monitoring, reporting, and regulatory compliance.

Currently, Dr. Iasonos focuses on two key areas of research:

Early Drug Development – Developing efficient methods and standards to expedite the early phases of drug development.

Predictive Models in Oncology – Leveraging predictive models to identify high-risk individuals most likely to benefit from novel interventions including surgical interventions.

In addition, she is deeply involved in efforts to address global cancer disparities through her work with the Global Cancer Disparities Initiative at Memorial Sloan Kettering Cancer Center (MSKCC).

For the past two decades, Dr. Iasonos has worked closely with oncologists, surgeons, and pathologists in the Gynecology service, contributing to over 200 peer-reviewed articles and multiple presentations at scientific meetings. She has played a significant role in various clinical protocols, including vaccine trials in ovarian cancer and studies evaluating targeted therapies, immunotherapies, and CAR T-cell therapies. Part of this work has been funded by the Ovarian Program Project for which Dr Iasonos has served as the lead of the Biostatistics Core for a decade, and she has been part of numerous P01, R01 and SPORE applications in gynecological cancers.

Dr. Iasonos is also highly involved in clinical research governance. She has assumed several roles in compliance at her institution. Among other responsibilities, Dr Iasonos has created and implemented several SOPs, identified, and trained new members for scientific protocol review committees and has served in leadership roles that review trial prioritization and clinical research administration. She is currently the chair of the Data Safety Monitoring Board at MSKCC and serves on several external DSMBs. As a co-chair of the Research Council, she has helped develop guidelines and policies to ensure the scientific integrity of clinical research protocols including sponsored trials. She has been an invited speaker on several FDA-AACR public workshops on optimizing dosages for oncology drug products or on tumor

agnostic drug development.

On an international scale, Dr. Iasonos collaborates with leading research teams from institutions such as University College London, Sorbonne University, Heidelberg University Hospital, and African oncology research group to advance educational and research efforts, particularly in Nigeria.

An advocate for mentoring and career development, Dr. Iasonos has held leadership roles on the Junior Faculty Council and the Medical Staff Advisory Council (elected position) at MSKCC. She is a dedicated mentor to early and mid-career scientists and clinician scientists across various disciplines. She has recently received the Values in action innovation badge award from MSKCC for her mentorship of a start-up company as part of the MSK Innovation Hub Challenge. She recently completed her term as the Chair of the Continuing Education Committee of the American Statistical Association, Biometrics section.

In addition to her research and leadership roles, Dr. Iasonos is the Deputy Editor of the *Journal of Clinical Oncology* and an elected member of the Society of Clinical Trials Board of Directors. She has been honored with several prestigious awards, including Fellow of the American Society of Clinical Oncology (2024) and Fellow of the Society of Clinical Trials (2022). She has recently been elected as the president-elect of the Society of Clinical Trials (2025).

## Publications

Selected peer-reviewed publications:

Iasonos A, O'Quigley J. Dose expansion cohorts in Phase I trials. *Stat Biopharm Res.*

2016;8(2):161-170. Epub 2016 Jun 2. PubMed PMID: 27516848; PubMed Central PMCID: PMC4976787.

Iasonos A, O'Quigley J. Clinical trials: Early phase clinical trials-are dose expansion cohorts needed? *Nat Rev Clin Oncol.* 2015 Nov;12(11):626-8. doi:10.1038/nrclinonc.2015.174. Epub 2015 Oct 6. PubMed PMID: 26441082; PubMed Central PMCID: PMC4758199.

Satagopan JM, Iasonos A. Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale. *Contemp Clin Trials.* 2017 Feb 22. pii: S1551-7144(16)30093-3. doi: 10.1016/j.cct.2017.02.007. [Epub ahead of print] PubMed PMID: 28254404.

Iasonos A, O'Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. *J Clin Oncol.* 2014 Aug 10;32(23):2505-11. doi: 10.1200/JCO.2013.54.6051. Epub 2014 Jun 30. Review. PubMed PMID: 24982451; PubMed Central PMCID: PMC4121508.

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol.* 2008 Mar 10;26(8):1364-70. doi: 10.1200/JCO.2007.12.9791. Review.

[Visit PubMed for a full listing of Alexia Iasonos' journal articles](#)

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

## My Downloads

- [R code Journal of the Royal Statistical Society entitled 'Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events'.](#)
- [Time to publication of oncology trials and why some trials are never published](#)

## My Pages

- [Is the Continual Reassessment Method Superior to the Standard 3+3 Dose Escalation Scheme?](#)
- [Phase I Workshop](#)

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Alexia Iasonos discloses the following relationships and financial interests:

- Chapman and Hall  
Intellectual Property Rights
- Intelligencia Inc.  
Professional Services and Activities (Uncompensated)
- Journal of Clinical Oncology  
Professional Services and Activities
- Mirati Therapeutics  
Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#). For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org).

[View all disclosures \(<https://www.mskcc.org/disclosures>\)](https://www.mskcc.org/disclosures)

---

© 2026 Memorial Sloan Kettering Cancer Center